Fundraising FoxMedical Incubator Japan K.K.
Venture capitalTokyo · Series A–Series B · 11 people tracked
Find your way into Medical Incubator Japan K.K.
Sign up to find every way you can get introduced to Medical Incubator Japan K.K.
- Your email: who you already know at Medical Incubator Japan K.K., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Medical Incubator Japan K.K. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
MIJ is a professional group specializing in healthcare investment. It invests in domestic and international startups developing first-in-class or best-in-class pharmaceuticals, spanning the latest technologies such as regenerative medicine and gene therapy through to small-molecule fields, as well as startups building devices and digital health services that bring innovation to the delivery of medical care. The firm combines global sourcing capabilities, evaluation expertise from healthcare business and investment professionals, and commercialization support intended to lead investments to success, aiming to bring hope to patients and returns to investors.
Source: firm website, verified Oct 1, 2026.
Team · 11 people
from the firm's websiteWhat they invest in
from 9 of 19 portfolio companiesHealthtech ×9Biotech ×8Medical Devices ×6Deep Tech ×4Digital Health ×2AI & Machine Learning ×1EdTech ×1Enterprise Software ×1
HQs:Japan×5United States×2United Kingdom×1
Investments · 19 tracked
founders shown can be your intro pathDermatology-focused R&D company using a proprietary nanoformulation technology to deliver drugs efficiently to hard-to-reach tissues like skin and nails.
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesModi VenturesPathway BioventuresSound Bioventures4BIO Capital+1 more
DiscGenics develops an allogeneic, injectable disc progenitor cell therapy (IDCT/rebonuputemcel) for painful lumbar degenerative disc disease, currently advancing toward a Phase III clinical program.
BiotechHealthtechMedical DevicesSalt Lake City, US
Dr. Valery Kukekov(Co-founder)Kevin T. Foley, M.D.(Co-founder; Chief Medical Officer, Director)Flagg Flanagan(Chief Executive Officer & Chairman of the Board)inBob Wynalek(COO & Board Member)in
Co-investorsMitsubishi UFJ Capital
Heartseed develops cardiac regenerative medicine, creating heart muscle cells from iPS cells for transplantation to treat heart failure, with its lead pipeline HS-001 nearing clinical trials.
BiotechHealthtechMedical Devices
Keiichi Fukuda(代表取締役社長 (President & CEO))
Co-investorsAngel Bridge Co.,Ltd.Astellas Venture Management LLCKeio Innovation InitiativeSMBC Venture CapitalSumitomo Mitsui Trust nvestment Co. Ltd.UTokyo Innovation Platform Co. Ltd.
Danish biotech developing non-opioid restorative treatments for chronic pain, hearing loss and sensory neuron disorders.
Co-investorsEIR VenturesIndaco Venture PartnersNovo Holdings
IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Kari Nadeau(Founder)Bruce Hironaka(Founder)Derek Croote(Founder)Stephen Quake(Founder)
Co-investorsKhosla VenturesAllerfund Ventures, LlcFemHealth VenturesGlobal BrainShangBay Capital LLCAlexandria+1 more
ILC Therapeutics is a biotechnology company developing hybrid interferon therapeutics, including its Alfacyte product, based on an interferon platform.
BiotechDeep TechHealthtechMedical DevicesGlasgow, GB
Owain Millington(Chief Executive Officer)in
Co-investorsEos Advisory
CellGen Tech develops cell-based medicines for rare and intractable diseases by engineering human adipose cells to produce therapeutic proteins.
BiotechDeep TechHealthtechMedical DevicesChiba, JP
麻生雅是(代表取締役社長 (President & CEO))
Onodera develops AAV vector platforms for gene therapy research targeting neurological conditions.
BiotechDeep TechDigital HealthHealthtechMedical Devices川崎市, JP
佐久間 陽介(Representative Director / President Executive Officer)浅井 克仁(Director / Chairman Executive Officer)
CareNet is a medical platform provider serving physicians and healthcare professionals in Japan with clinical information, medical education content, and pharmaceutical marketing support tools.
Digital HealthEdTechEnterprise SoftwareHealthtechMarketing TechMedical DevicesTokyo, JP
藤井 勝博(Group CEO / Representative Director)
Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development.
BiotechDeep TechHealthtechTokyo, JP
Haruhiko Morita(代表取締役CEO (President & CEO))
Co-investorsNippon Venture CapitalShinsei Capital PartnersSMBC Venture CapitalUTokyo Innovation Platform Co. Ltd.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CareNet, Inc.CellGenTech, Inc.Cytospire Therapeutics LimitedModalis Therapeutics (株式会社モダリス)Modalis Therapeutics CorporationSanBio Co., Ltd.セルジェンテック (CellGenTech)
Frequently asked questions
- How many investments has Medical Incubator Japan K.K. made?
- Medical Incubator Japan K.K. has 19 tracked investments.
- What stage does Medical Incubator Japan K.K. invest at?
- Medical Incubator Japan K.K. invests at the Series A, Series B stages.
- What sectors does Medical Incubator Japan K.K. focus on?
- Medical Incubator Japan K.K. focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Medical Incubator Japan K.K. located?
- Medical Incubator Japan K.K. is headquartered in Tokyo, JP.
- Who does Medical Incubator Japan K.K. co-invest with?
- Medical Incubator Japan K.K. most often shares deals with SMBC Venture Capital, UTokyo Innovation Platform Co. Ltd., Allerfund Ventures, Llc, among 21 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.